Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)

Abstract Introduction Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical and clinical trials have suggested that antiangiogenic t...

Full description

Bibliographic Details
Main Authors: Bo Zhang, Hua Zhong, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Weimin Wang, Tianqing Chu, Liwen Xiong, Wei Zhang, Huimin Wang, Xueyan Zhang, Baohui Han
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:The Clinical Respiratory Journal
Subjects:
anti‐angiogenesis
check‐point inhibitors
ES‐SCLC
maintenance treatment
Online Access:https://doi.org/10.1111/crj.13715

Internet

https://doi.org/10.1111/crj.13715

Similar Items